"ASSESSMENT OF THE EFFICIENCY OF BIOREGULATOR DRUGS IN THE TREATMENT OF OSTEOARTHRITIS IN THE CLIMACTERIC PERIOD WITH ENDOTHELIAL DYSFUNCTION"

Abstract

In recent years, molecular bioregulatory drugs have come into practice for the treatment of OA. Bioregulatory drugs consist of several components (usually of natural origin) that affect many processes simultaneously as part of the anti inflammatory response. Recently, the use of bioregulatory drugs Traumel S and Zeel T in the pathogenetic treatment of OA has justified in clinical practice. Traumel S is a bioregulatory agent of plant and mineral origin, containing 14 components, having anti-inflammatory, exudative, regenerating, analgesic and immunomodulatory effects. The purpose of the study is to evaluate the effectiveness of bioregulatory drugs in the treatment of osteoarthritic patients in the climacteric period with endothelial dysfunction. From 2020 to 2022, 105 climacteric female patients with a confirmed diagnosis of OA of the knee joint, registered in the arthrological IADC department of the multidisciplinary clinic of the Tashkent Medical Academy (TMA), receiving inpatient treatment in the departments of cardiorheumatology and rheumatology, were involved in this research work. They analyzed the clinical course of the disease and the results of laboratory and instrumental examinations. For prospective analysis, the patients were divided into two groups: Group I consisted of female patients with premenopausal OA. Group II consisted of postmenopausal female patients with OA during menopause. In the obtained results, the clinical and laboratory activity indicators of the disease reliably decreased in a statistically significant manner in the group of patients treated with bioregulatory drugs compared to traditional treatment. Also, indicators of endothelial dysfunction were improved. In UVD and MRI, degenerative changes in bones and joints showed positive dynamics. In conclusion, in the treatment of OA patients in the climacteric period, the use of bioregulatory drugs (Traumel S and Zeel T) in addition to traditional treatment reduces the frequency of degenerative changes in the joints by reducing the clinical laboratory activity level of the disease, improving endothelial dysfunction, and improving the quality of life of patients.